Biomaterial Database

Recurrent agranulocytosis following carbimazole and propylthiouracil therapy. 1988

S Ostlere, and G H Apthorp

Agranulocytosis is an infrequent but potentially fatal complication of anti-thyroid drugs. There is little information regarding the use of a second anti-thyroid drug when initial therapy results in agranulocytosis. This report summarises a case of recurrent agranulocytosis following the consecutive administration of carbimazole and propylthiouracil.

UI	MeSH Term	Description	Entries
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D011441	Propylthiouracil	A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)	6-Propyl-2-Thiouracil,6 Propyl 2 Thiouracil
D012008	Recurrence	The return of a sign, symptom, or disease after a remission.	Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002231	Carbimazole	An imidazole antithyroid agent. Carbimazole is metabolized to METHIMAZOLE, which is responsible for the antithyroid activity.	Carbimazole Henning,Neo Tomizol,Neo-Mercazole,Neo-Thyreostat,Neomercazole
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000380	Agranulocytosis	A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	Granulocytopenia,Agranulocytoses,Granulocytopenias